Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.

Kidney Transplant Acute Rejection

Any Patient Receiving a Kidney Transplant May Be at Risk for Acute Rejection1

Both recipient and donor risk factors should be considered when evaluating transplant risk.2,3
Both recipient and donor risk factors should be considered when evaluating risk for acute rejection of a kidney transplant chart

Acute Rejection Can Negatively Impact Graft Survival and Is a Primary Cause of Graft Failure After Transplant6,7

Acute rejection is the cause of nearly 20% of all graft failures in the first year after kidney transplant image While acute rejection now occurs in
less than 10% of kidney transplants,
it remains the cause of nearly 20%
of all graft failures in the first year
after transplant
 6,7
Protection against acute rejection is a critical step to avoid kidney loss8

Induction Immunosuppressive Therapy Can Help Prevent Acute Rejection

Induction therapy is a short-term treatment with a biologic agent administered before reperfusion of the donor kidney.1

Two Classes of Agents Are Approved for Induction Therapy1,9


Goals of Therapy1:

  • Deplete T cells or modulate their responses at the time of allograft antigen presentation
  • Improve the efficacy of immunosuppression by reducing the incidence and the severity of acute rejection
  • Allow a reduction in other maintenance agents in the regimen, such as calcineurin inhibitors or corticosteroids
Learn How Thymoglobulin
May Suppress the Immune Response.
Learn More

Important Safety Information for Thymoglobulin
[Anti-thymocyte Globulin (Rabbit)]:

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Important Safety Information for Thymoglobulin [Anti-thymocyte Globulin (Rabbit)]:

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Click here for full Prescribing Information including Boxed WARNING.

References:
  1. Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-157.
  2. Hart A, Smith JM, Skeans MA, et al. Am J Transplant. 2016; 2:11-46.
  3. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant. 2015;15 Suppl 2:1-34.
  4. Lebranchu Y, Baan C, Biancone L, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int. 2014;27(2):129-138.
  5. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant. 2005;5(11):2740-2744.
  6. Schnitzler MA, Johnston K, Axelrod D, Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. Transplantation. 2011;91(12):1347-1356.
  7. El-Zoghby ZM, Stegall MD, Lager DJ, et al. identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-535.
  8. Lentine KL, Schnitzler MA, Xiao H, Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Trials. 2015;16:365.
  9. Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol. 2003;3(10):831-838.